The Quantellect read.As of Nov 19, 2026, 16 active firms cover Gilead Sciences Inc: 13 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $126.00 to $180.00, a moderate spread. The average target of $160.50 sits 5% below the current $168.98. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.14 next quarter toward $10.13 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 active firms
Buy
Strong Buy00%
Buy1381%
Neutral319%
Sell00%
Strong Sell00%
Based on 16 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$160.50
-5.0% downside
Average target across 16 active firms as of Nov 19, 2026 vs $168.98 current
Highest Target$180.00
Average Target$160.50
Lowest Target$126.00
Detailed analyst forecasts for GILD
Showing 1–16 of 16 named analysts shown · 16 active firms in the rating projection
As of Nov 19, 2026, 13 of 16 active firms rate GILD a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GILD EPS & revenue forecast
EPS · NEXT QUARTER
$2.14
Range $1.90 – $2.26 · 6 analysts · +5% YoY
Next period, 6 analysts expect Gilead Sciences Inc to earn $2.14 a share (range $1.90 – $2.26), versus $2.03 a year earlier. Full-year consensus is $-0.98, growing to $10.13 the year after.
REVENUE · NEXT QUARTER
$7.4B
Range $7.3B – $7.6B · 6 analysts · +7% YoY
Revenue is expected to reach $7.4B (range $7.3B – $7.6B), +6.9% year-over-year. Full-year consensus is $31.4B, rising to $33.6B next year.
Top analysts covering Gilead Sciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GILD.
#1
Terence Flynn
Morgan Stanley · Rank #222
Buy
$183.00+8.3% to target
Overall win rate
36%
+ Follow
#2
Joseph Stringer
Needham · Rank #256
Buy
$200.00+18.4% to target
Overall win rate
36%
+ Follow
#3
CS
Chris Schott
JP Morgan · Rank #287
Buy
$190.00+12.4% to target
Overall win rate
41%
+ Follow
#4
Matthew Harrison
Morgan Stanley · Rank #393
Buy
$163.00-3.5% to target
Overall win rate
44%
+ Follow
#5
Daina Graybosch
Leerink Partners · Rank #396
Neutral
$129.00-23.7% to target
Overall win rate
41%
+ Follow
GILD stock forecast FAQ
What is GILD's average 12-month price target?+
The 16 active firms with a live target average $160.50 for Gilead Sciences Inc over the next 12 months, ranging from a $180.00 high to a $126.00 low, as of Nov 19, 2026.
Is GILD stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 16 active firms as of Nov 19, 2026, 13 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for GILD?+
The Street-high target is $180.00 (Jefferies), and the Street-low is $126.00 (RBC Capital). The average of all 16 active-firm targets is $160.50.
How many active Wall Street firms cover GILD?+
16 active firms have a recognized rating on Gilead Sciences Inc as of Nov 19, 2026, and 16 active firms carry a live 12-month price target.
Who is the most accurate analyst covering GILD?+
Among analysts who currently cover GILD, Terence Flynn of Morgan Stanley has the strongest overall Quantellect track record (Rank #222). Their current call is Buy with a $183.00 target.
What is Gilead Sciences Inc's projected EPS for next quarter?+
The consensus estimate is $2.14 per share (range $1.90 – $2.26) across 6 analysts. Full-year EPS is projected at $-0.98, rising to $10.13 the following year.
How much revenue is Gilead Sciences Inc expected to report next quarter?+
Consensus revenue is $7.4B (range $7.3B – $7.6B). Full-year revenue is projected at $31.4B, growing to $33.6B next year.
Have analysts been upgrading or downgrading GILD lately?+
As of Nov 19, 2026, 13 of 16 active firms rate GILD a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GILD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.